Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,230.12
(
0.29%
)
US TECH 100
26,942.00
(
0.87%
)
Dow Jones
49,499.27
(
-0.31%
)
Brent Oil
107.80
(
0.00%
)
Bitcoin
78,431.20
(
-0.32%
)
News Focus
News Focus

Replies to post #818156 on NorthWest Biotherapeutics Inc (NWBO)

Replies to #818156 on NorthWest Biotherapeutics Inc (NWBO)
icon url

SkyLimit2022

03/17/26 12:56 PM

#818169 RE: exwannabe #818156

High-Ranking Officer e❌,

Thanks for sharing your free x-pertise 😶

And thanks for highlighting the topic of ovarian cancer…

The forthcoming COMBO trial for ovarian cancer involves the polarized aDC1 platform …

The NIH database entry for Dr. Kalinski’s previous grant award may provide insight into the potential design of the ovarian cancer combo trial:

🇺🇸U.S. National Institutes of Health Grants Database



Perhaps even more valuable than the funding itself, the validation that comes with a rigorously peer-reviewed grant award is immensely significant!



Dr. Kalinski




University of Pittsburgh Hillman Cancer Center



The polarized aDC1 platform has also been studied in breast cancer with promising results…

The Dava Oncology Breast Cancer Summit was a noteworthy event last August—deserved more attention. NWBO’s polarized aDC1 platform technology was featured, & combo with checkpoint blockade was highlighted!

Dr. Shipra Gandhi was the principal on the aDC1 combo trial NCT04348747 before joining the Winship Cancer Institute at Emory University. Dr. Sheheryar Kabraji is the current principal of the study, & he also attended the conference.







ASCO 2025 Abstract



















AI Fact-Checking
Bullish
Bullish